Bristol Myers Squibb Reports Q1 2024 Net Loss and Announces Plan to Cut 2,200 Jobs Amid Strategic Restructuring

　　【Pharmaceutical Network Enterprise NewsOn April 25, Bristol Myers Squibb (BMS) released its Q1 2024 financial report. The report showed that the company's sales in Q1 2024 increased by 5% to $11.9 billion, surpassing the previous expectation of $11.5 billion. Notable increases were seen in Reblozyl (+72%, to $354 million) and Opdualag (+76%, to $206 million). Opdivo's revenue declined by 6% to $2.1 billion. However, the company reported a loss per share of $4.40, compared to earnings per share of $2.05 in the same period last year, shifting from profit to loss, while the market expected a loss per share of $4.44.
 

In the first quarter report, BMS also stated that approximately 2,200 employees will be affected by the company's cost-cutting measures, which aim to save about $1.5 billion by the end of 2025. BMS noted that the plan includes restructuring the organizational management structure and optimizing the product pipeline.
 

BMS-related sources also pointed out that "the majority" (2/3) of cost savings will come from BMS's traditional R&D business, rather than the synergistic assets recently acquired. Sources indicated that BMS has so far halted or outsourced the development of 12 projects, including the follow-up version of its immunotherapy Yervoy, SIRPα- and BET-targeted drugs, and will continue to review its pipeline within the remainder of this year.
 

In its restructuring efforts, Bristol-Myers Squibb (BMS) is seeking to optimize its operations by reducing management levels and implementing other cost-cutting measures. It has been reported that after BMS acquired Mirati Therapeutics for $4.8 billion last October, the company initiated layoffs earlier this year, planning to lay off 423 employees in San Diego.
 

BMS Company also stated that, in terms of its investment channels, the saved funds will be reinvested into potential blockbuster drugs. It is reported that while BMS continues to optimize its operations, it actively expands its product line through acquisitions. For instance, in 2023, BMS spent $14 billion to acquire Karuna Therapeutics—a company developing a new drug for schizophrenia, which is expected to gain U.S. approval this year. Additionally, BMS acquired RayzeBio Inc., a radiopharmaceutical manufacturer, for $4.1 billion, and Mirati Therapeutics Inc., a cancer drug manufacturer, for $4.8 billion.
 

In the face of these major acquisitions, Bristol-Myers Squibb has lowered its profit forecast for 2024. The company expects its adjusted earnings per share for the full year to be between $0.40 and $0.70, down from the previous range of $7.10 to $7.40, in line with analysts' average expectation of $0.67.
 

Analysts pointed out that layoffs are one of the powerful ways for companies to reduce costs and increase efficiency. By cutting staff and eliminating redundant pipelines, companies can save costs and concentrate resources, which will strongly promote corporate restructuring and transformation. The factors affecting layoffs in the biopharmaceutical field mainly include industry cycles and economic environment, strategic adjustments and business focus, R&D investment and return expectations, and industry integration and mergers and acquisitions.
 

It is reported that, in addition to Bristol-Myers Squibb (BMS), Novartis, Bayer, Pfizer, and Biogen have all announced large-scale layoffs over the past year, while Amgen, Gilead Sciences, and Boehringer Ingelheim have implemented smaller-scale layoffs.
 

Reportedly, on April 9 this year, Novartis also announced that it would cut as many as 680 jobs in its development organization, which is responsible for helping the company bring drugs to market. Novartis stated that over the next two to three years, about 440 jobs will be cut in Switzerland and 240 in the United States. In January this year, Bayer said that as part of its restructuring efforts to reverse the group's performance, the company will carry out "significant layoffs" among its employees in Germany by the end of 2025, mainly targeting management functions.
 

Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.